Clinical Outcomes of a Phase II, Multi-Institutional Cesium-131 Premanent Prostate Brachytherapy Trial

Brachytherapy

April 29, 2007

Dr. Prestidge, from San Antonio, reported in 2007 on the ground-breaking 100-patient clinical study known as the “Cesium Monotherapy Trial.”They noted only one (1%) RTOG grade 3 rectal complication, and also noted the duration of urinary side-effects to last approximately six months. Symptoms were statistically correlated to the dose of Cs-131 delivered.

Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.

Authors: Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V.

Is there Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope?

Authors: S.G. DeFoe, S. Beriwal, R. Smith, R. Benoit

Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131

Authors: Glaser SM, Chen KS, Benoit RM, Smith RP, Beriwal S.

Patient Information

Clinician Information

Cesium 131 Products

Why Theranostics?

Pipeline

Clinical Outcomes of a Phase II, Multi-Institutional Cesium-131 Premanent Prostate Brachytherapy Trial

Authors

Related posts

Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.

Is there Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope?

Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131

Search

Recent Posts

Archives

Company

Brachytherapy

Theranostics

Newsletter

Email newsletter sign-up

Company

Newsletter

Email newsletter sign-up